I have exited the most of the allocation as uptick in revenues and profit is seems to be impossible in the FY25 itself.
Something wrong with capsules business also, earlier they were telling sluggish demand due to pharma companies are with excess inventory. Now all pharma company numbers are good still they are not able to see jump in numbers, this could be due to price erosion and excess supply from competitors also.
I will revisit once API segment make some +ve EBITDA
Subscribe To Our Free Newsletter |